19809-30-4

Basic information

• Product Name: 1H-Benzimidazole-1-aceticacid,methylester(9CI)
• Synonyms: 1H-Benzimidazole-1-aceticacid,methylester(9CI);1H-BENZIMIDAZOLE-1-ACETIC ACID, METHYL ESTER;Methyl 2-(1H-benzo[d]iMidazol-1-yl)acetate
• CAS NO: 19809-30-4
• Molecular Formula: C10H10N2O2
• Molecular Weight: 190.2
• Product Categories: BENZIMIDAZOLE
• Mol File: 19809-30-4.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Benzimidazole-1-aceticacid,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-1-aceticacid,methylester(9CI)(19809-30-4)
• EPA Substance Registry System: 1H-Benzimidazole-1-aceticacid,methylester(9CI)(19809-30-4)

Safety Data

• Hazardous Substances Data: 19809-30-4(Hazardous Substances Data)

Usage

Heterocyclic compound

A compound consisting of a ring structure containing both carbon and non-carbon atoms, such as nitrogen In this case, the benzimidazole ring structure contains both carbon and nitrogen atoms.

Synthesis of pharmaceuticals and pesticides

1H-Benzimidazole-1-acetic acid, methyl ester (9CI) is commonly used as an intermediate in the synthesis of various pharmaceuticals and pesticides due to its heterocyclic structure and biological activity.

Antiviral, antifungal, and antiparasitic properties

The benzimidazole ring structure is known for its ability to inhibit the growth and replication of viruses, fungi, and parasites, making it a valuable component in the development of medications and pesticides.

Potential applications in medicinal chemistry and drug development

The biological activities and structural features of 1H-Benzimidazole-1-acetic acid, methyl ester (9CI) make it a promising candidate for further research and development in the field of medicinal chemistry.

Improved solubility and bioavailability

The methyl ester form of 1H-benzimidazole-1-acetic acid may offer better solubility in water and increased absorption in biological systems, which can be advantageous for pharmaceutical applications.

Upstream product

• 51-17-2 benzoimidazole 
• 96-34-4 methyl chloroacetate 
• 96-32-2 bromoacetic acid methyl ester 

Downstream Products

• 791806-33-2 C₁₀H₁₀N₆S 
• 876712-40-2 3-(1-benzimidazolylmethyl)-6-p-tolyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 

Relevant articles and documents

Identification of a novel SHP-2 protein tyrosine phosphatase inhibitor

The Src homology 2 (SH2) domain-containing phosphatase 2 (SHP-2) is a nonreceptor protein tyrosine phosphatase (PTP) involved in extracellular- regulated kinase (ERK) activation. Recent studies have shown that gain-of-function mutations in SHP-2 are associated with several diseases, including LEOPARD syndrome, Noonan syndrome, and juvenile myelomonocytic leukemia. In this study, we identified the novel SHP-2 inhibitor 3-(1-benzimidazolylmethyl)-6-p-tolyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole (MLS-001). SHP-2 activity was inhibited by MLS-001, whereas other types of PTPs, namely ACP1, CDC25A, DUSP3, DUSP14, DUSP18, DUSP22, DUSP23, DUSP26, and SSH3, were not. Furthermore, TCPTP and SHP-1 that are closely related to SHP-2 were not inhibited by the inhibitor. Kinetic studies with MLS-001 and SHP-2 revealed a competitive inhibition. The SHP-2 expressing cells treated with MLS-001 demonstrated reduced SHP-2 phosphatase activity, thereby suggesting that MLS-001 effectively passes through cell membranes. In addition, MLS-001 reduced SHP-2-mediated phosphorylation in the activation loop of ERK in cells. Therefore, MLS-001 could be a lead compound for developing a potent SHP-2 inhibitor.